Showing results (1161-1170 of 1,427) with videos related to

Sort By:
Pageof 143
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
British Journal of Cancer|December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
British Journal of Cancer|October 13, 2006
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasI Duran, J Kortmansky, D Singh, et al.
JACC. Clinical Electrophysiology|May 19, 2023
Performance of the REAL-AF Same-Day Discharge Protocol in Patients Undergoing Catheter Ablation of Atrial FibrillationAnil Rajendra, Jose Osorio, Juan C Diaz, et al.
Cancer Research Communications|March 26, 2026
Pre-Clinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case ReportNikolina Radulovich, Pamela Soberanis Pina, Molly L Udaskin, et al.
The Lancet. Oncology|January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialDan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Gynecologic Oncology|November 20, 2018
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancerAntonio González Martín, Amit M Oza, Andrew C Embleton, et al.
Surgery|April 1, 2014
Laparoscopic-assisted versus open pancreaticoduodenectomy: early favorable physical quality-of-life measuresRussell C Langan, Jay A Graham, Anne B Chin, et al.
Antimicrobial Resistance and Infection Control|January 8, 2021
The Clean pilot study: evaluation of an environmental hygiene intervention bundle in three Tanzanian hospitalsGiorgia Gon, Abdunoor M Kabanywanyi, Petri Blinkhoff, et al.
Nature Communications|May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trialAna C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
Pageof 143